Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Decker

Showing results (31-40 of 180) with videos related to

Pageof 18
Sort By:
Clinical Chemistry and Laboratory Medicine|December 22, 2022
Principles of ideal diagnostic regulation and the IVDRAnna Margareta Hallersten, Nicholas Michael Decker, Yasha Huang
Bioorganic & Medicinal Chemistry Letters|September 2, 2006
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitorsYvonne Schott, Michael Decker, Hans Rommelspacher, et al.
ACS Medicinal Chemistry Letters|October 16, 2024
Correlating Predicted Reactivities with Experimental Inhibition Data of Covalent ChlaDUB1 InhibitorsThomas Zimmermann, Erik Endres, Christoph Sotriffer, et al.
Journal of Medicinal Chemistry|March 17, 2006
Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonistPatrick Mohr, Michael Decker, Christoph Enzensperger, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|September 28, 2007
6-aryl-4-oxohexanoic acids: synthesis, effects on eicosanoid biosynthesis, and anti-inflammatory in vivo-activitiesKhaled Abouzid, Petra Frohberg, Jochen Lehmann, et al.
European Journal of Medicinal Chemistry|June 9, 2004
Dopamine/serotonin receptor ligands. Part VIII: the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testingsMichael Decker, Klaus-Jürgen Schleifer, Martin Nieger, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate TransferFouad H Darras, Beata Kling, Jörg Heilmann, et al.
The Journal of General Physiology|January 28, 2009
Decremental response to high-frequency trains of acetylcholine pulses but unaltered fractional Ca2+ currents in a panel of "slow-channel syndrome" nicotinic receptor mutantsSergio Elenes, Michael Decker, Gisela D Cymes, et al.
Journal of Orthopaedic Surgery (Hong Kong)|March 4, 2026
What you see is what you get: High degree of alignment accuracy with hand-held computer-aided technology when comparing intraoperative alignment to postoperative radiographs in direct anterior total hip arthroplastyThomas Geissler, Jacob Hall, Nicolas Koerber, et al.
Angewandte Chemie (International Ed. in English)|March 29, 2022
Enlightening the "Spirit Molecule": Photomodulation of the 5-HT<sub>2A</sub> Receptor by a Light-Controllable N,N-Dimethyltryptamine DerivativeHubert Gerwe, Feng He, Eline Pottie, et al.
Pageof 18

Showing results (31-40 of 180) with videos related to

Sort By:
Pageof 18
Clinical Chemistry and Laboratory Medicine|December 22, 2022
Principles of ideal diagnostic regulation and the IVDRAnna Margareta Hallersten, Nicholas Michael Decker, Yasha Huang
Bioorganic & Medicinal Chemistry Letters|September 2, 2006
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitorsYvonne Schott, Michael Decker, Hans Rommelspacher, et al.
ACS Medicinal Chemistry Letters|October 16, 2024
Correlating Predicted Reactivities with Experimental Inhibition Data of Covalent ChlaDUB1 InhibitorsThomas Zimmermann, Erik Endres, Christoph Sotriffer, et al.
Journal of Medicinal Chemistry|March 17, 2006
Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonistPatrick Mohr, Michael Decker, Christoph Enzensperger, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|September 28, 2007
6-aryl-4-oxohexanoic acids: synthesis, effects on eicosanoid biosynthesis, and anti-inflammatory in vivo-activitiesKhaled Abouzid, Petra Frohberg, Jochen Lehmann, et al.
European Journal of Medicinal Chemistry|June 9, 2004
Dopamine/serotonin receptor ligands. Part VIII: the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testingsMichael Decker, Klaus-Jürgen Schleifer, Martin Nieger, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate TransferFouad H Darras, Beata Kling, Jörg Heilmann, et al.
The Journal of General Physiology|January 28, 2009
Decremental response to high-frequency trains of acetylcholine pulses but unaltered fractional Ca2+ currents in a panel of "slow-channel syndrome" nicotinic receptor mutantsSergio Elenes, Michael Decker, Gisela D Cymes, et al.
Journal of Orthopaedic Surgery (Hong Kong)|March 4, 2026
What you see is what you get: High degree of alignment accuracy with hand-held computer-aided technology when comparing intraoperative alignment to postoperative radiographs in direct anterior total hip arthroplastyThomas Geissler, Jacob Hall, Nicolas Koerber, et al.
Angewandte Chemie (International Ed. in English)|March 29, 2022
Enlightening the "Spirit Molecule": Photomodulation of the 5-HT<sub>2A</sub> Receptor by a Light-Controllable N,N-Dimethyltryptamine DerivativeHubert Gerwe, Feng He, Eline Pottie, et al.
Pageof 18